(Q37872630)

24 August 2017

0 references

1 reference

title

MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis (English)

1 reference

24 August 2017

0 references

1 reference

Yan Li

1

1 reference

24 August 2017

Hongjin Zhao

2

1 reference

24 August 2017

Li Sun

3

1 reference

24 August 2017

Linjuan Huang

4

1 reference

24 August 2017

Qifeng Yang

5

1 reference

24 August 2017

Beihua Kong

6

1 reference

24 August 2017

publication date

4 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

24

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

57-64

1 reference

Current issues in the management of endometrial cancer.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Amplification of a gene encoding a p53-associated protein in human sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

The MDM2 gene amplification database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

The p53 and Mdm2 families in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Mdm2 promotes the rapid degradation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

MDM2 SNP309 is associated with endometrial cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

The Sequence of the Human Genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Regulation of p53 stability by Mdm2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

The p53 pathway: positive and negative feedback loops

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Mdm2 affects genome stability independent of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Detection of functional single-nucleotide polymorphisms that affect apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-011-0013-4

Abnormal expression of MDM-2 in breast carcinomas

21 January 2018

1 reference

12 December 2020

Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer

1 reference

12 December 2020

p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.

1 reference

12 December 2020

Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells

1 reference

12 December 2020

p53: an overview of over two decades of study.

1 reference

12 December 2020

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

12 December 2020

Distinct promoter usage of mdm2 gene in human breast cancer

1 reference

12 December 2020

10.1007/S13577-011-0013-4

Identifiers

DOI

1 reference

24 August 2017

1 reference